Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis

Area of Science:

• Neuroimmunology
• Molecular Biology
• Biomarker Discovery

Background:

• MicroRNAs (miRNAs) are increasingly recognized for their role in multiple sclerosis (MS) pathogenesis.
• Up-regulated miRNAs may serve as diagnostic signatures for MS.
• Interleukin-17 (IL-17), a key inflammatory cytokine, is a focus in MS research.

Purpose of the Study:

• To investigate the expression levels of miR-18b in relation to IL-17A in relapsing-remitting MS (RRMS) patients.
• To compare miR-18b and IL-17A levels during relapse and remission phases of RRMS.

Main Methods:

• Quantitative real-time PCR was used to measure serum miR-18b levels.
• Enzyme-linked immunosorbent assay (ELISA) was employed to quantify serum IL-17A levels.
• The study included 28 RRMS patients and 26 age/sex-matched controls.

Main Results:

• Serum miR-18b expression was significantly higher in RRMS patients during relapse compared to remission and controls (P < 0.001).
• Serum IL-17A levels were also elevated in RRMS patients during relapse versus remission and controls (P < 0.001).
• No significant correlation was found between miR-18b and IL-17A levels in MS patients during relapse or remission.

Conclusions:

• The upregulation of miR-18b during relapse in RRMS suggests its potential involvement in the inflammatory processes of MS.
• The absence of correlation between miR-18b and IL-17A indicates that miR-18b might influence MS pathogenesis through distinct inflammatory pathways.